Nephrology - European Medical Journal

Continue

Nephrology

Filter
7 Mins
14 Mar 2024

Sparsentan for treatment of immunoglobulin A nephropathy: Latest study results

In patients with immunoglobulin A nephropathy, use of the endothelin 1 Type A/Ang II subtype 1 receptor antagonist sparsentan can decrease proteinuria and preserve kidney function
8 Mins
14 Mar 2024

Renal Replacement Therapy

End-stage liver disease (ESLD) represents a non-reversible, advanced stage of cirrhosis, where the hepatic architecture is distorted and…
8 Mins
7 Mar 2024

Interview: Smeeta Sinha

Smeeta Sinha National Clinical Director for Renal Medicine, NHS England, UK; Consultant Nephrologist, Northern Care Alliance NHS Foundation…
4 Mins
16 Feb 2024

Membranous Nephropathy and Pulmonary Tuberculosis

Mycobacterium tuberculosis causing glomerulonephritis (GN) is a rare occurrence, and its association has been seldom reported…
10 Mins
14 Dec 2023

Current Treatment and Emerging Solutions in IgA Nephropathy

IgAN, which can lead to CKD and kidney failure, is the most common form of primary glomerulonephritis, predominantly…
12 Mins
15 Aug 2023

Diagnosing Fabry Disease: Practical Clinical Recommendations and Guidance for Patients with Fabry Disease

This article was funded by Sanofi and is intended for healthcare professionals.
10 Mins
27 Jul 2023

Filling the Gap by Targeting the Gut: First Disease-Modifying Treatment Approved for IgA Nephropathy

Bengt Fellström, Uppsala University, Sweden, described the relationship between IgA nephropathy (IgAN) and gastrointestinal mucosal…
5 Mins
27 Jul 2023

Proteinuria as a Surrogate Endpoint for Disease Progression in IgA Nephropathy: Predicting Long-Term Treatment Effects of Sparsentan

IgA nephropathy (IgAN) is a rare, life-limiting disease for which there is significant unmet need. Until recently, drug development for…